MedTrace Logo

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer

NCT07528430 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2026-04-14

No results posted yet for this study

Summary

The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.

Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.

Conditions

  • Pancreatic Cancer, Advanced or Metastatic

Sponsors & Collaborators

  • EPOCH Epigenetics, Inc

    collaborator UNKNOWN

  • University of Maryland, Baltimore

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2032-06-30
Completion
2032-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07528430 on ClinicalTrials.gov